|
WO2020243443A1
|
|
Alk7 binding proteins and uses thereof
|
|
WO2020243448A1
|
|
Actrii-binding proteins and uses thereof
|
|
EP3807308A1
|
|
Bi-and tri-functional fusion proteins and uses thereof
|
|
EP3788067A1
|
|
Novel binders of tgfbeta-superfamily ligands and uses thereof
|
|
EP3788066A1
|
|
Multispecific binders of tgfbeta-superfamily ligands and uses thereof
|
|
WO2019191204A1
|
|
Follistatin polypeptides for the treatment of muscle contracture
|
|
WO2019157342A1
|
|
Methods for treating heterotopic ossification
|
|
WO2019136043A1
|
|
Single-arm co-receptor fusion proteins and uses thereof
|
|
AU2018354295A1
|
|
ALK7 binding proteins and uses thereof
|
|
US2019048063A1
|
|
Methods and compositions for modulating angiogenesis and pericyte composition
|
|
AU2018261131A1
|
|
TGF-beta receptor type II fusion proteins and uses thereof
|
|
EP3606562A1
|
|
Compositions and methods for treating spinal muscular atrophy
|
|
WO2018144968A1
|
|
Compositions and methods for treating heart failure
|
|
US2020306340A1
|
|
Tgfbeta and actrii antagonists for use in increasing immune activity
|
|
WO2018067873A2
|
|
Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
|
|
US2020055919A1
|
|
Variant actriib proteins and uses thereof
|
|
TW201813978A
|
|
ALK4:ACTRIIB heteromultimers and uses thereof
|
|
CA3039074A1
|
|
Compositions and method for treating kidney disease
|
|
CN109996817A
|
|
Reverse primitive gut embryogenesis polypeptide and application thereof
|
|
EP3490582A1
|
|
Methods and compositions for treating myelofibrosis
|
